A prospective feasibility study would be a practical first step, focusing on real-time assessment and ensuring the new working element's integration is safe and effective before broader clinical trials.

Inclusion Criteria:

• Diagnosed with benign prostatic hyperplasia (BPH) requiring surgical intervention.
• Prostate volume ≥40 cc (as assessed by transrectal ultrasound).
• No prior history of prostate cancer.

Exclusion Criteria:

• Patients with ongoing urinary tract infections.
• Prior prostate surgeries.
• Coagulation disorders or patients on long-term anticoagulation therapy.
• Known urethral strictures or other anatomical abnormalities complicating endoscopic procedures.

the study will include male patients aged ≥50 years who are diagnosed with benign prostatic hyperplasia (BPH) , prostate volume ≥40 cc without 4prior history of prostate cancer while patients with ongoing urinary tract infections, prior prostate surgeries, coagulopathy or urethral strictures were excluded.